Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price target on the stock.

CMPX has been the topic of several other reports. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Piper Sandler started coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Guggenheim assumed coverage on shares of Compass Therapeutics in a research report on Monday. They set a “buy” rating and a $12.00 price target on the stock. Finally, Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Price Performance

CMPX stock opened at $2.92 on Tuesday. The company has a market capitalization of $401.76 million, a P/E ratio of -7.89 and a beta of 1.17. Compass Therapeutics has a 12 month low of $0.76 and a 12 month high of $4.08. The firm’s fifty day simple moving average is $2.56 and its 200-day simple moving average is $1.93.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, sell-side analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently bought and sold shares of the company. Rovin Capital UT ADV purchased a new position in Compass Therapeutics in the 3rd quarter valued at $25,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics during the third quarter worth about $30,000. Tower Research Capital LLC TRC increased its holdings in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at $26,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics in the 4th quarter valued at $27,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.